Hsbc Holdings PLC Invests $12.92 Million in Qiagen N.V. $QGEN

Hsbc Holdings PLC purchased a new position in Qiagen N.V. (NYSE:QGEN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 322,819 shares of the company’s stock, valued at approximately $12,916,000.

Several other institutional investors also recently bought and sold shares of the company. Boston Partners bought a new stake in Qiagen during the 3rd quarter valued at about $179,450,000. Norges Bank bought a new position in shares of Qiagen in the fourth quarter worth approximately $166,500,000. Dimensional Fund Advisors LP purchased a new stake in shares of Qiagen during the third quarter valued at approximately $58,079,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after buying an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG increased its position in shares of Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after acquiring an additional 697,342 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Trading Up 0.1%

Shares of QGEN stock opened at $40.58 on Thursday. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The stock has a market capitalization of $8.36 billion, a P/E ratio of 21.19, a P/E/G ratio of 4.04 and a beta of 0.64. The firm’s 50 day moving average is $37.79 and its 200 day moving average is $42.19.

Qiagen (NYSE:QGEN) last announced its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.54. The business had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same period in the previous year, the business earned $0.56 EPS. Research analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were issued a $0.35 dividend. The ex-dividend date of this dividend was Tuesday, July 7th. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. Qiagen’s dividend payout ratio is presently 18.32%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $43.00 price objective on shares of Qiagen in a report on Thursday, April 30th. Barclays set a $38.00 target price on Qiagen and gave the stock an “equal weight” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price target on Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Berenberg Bank set a $45.50 price target on Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. Finally, Kepler Capital Markets set a $38.60 price target on Qiagen and gave the company a “hold” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $43.34.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.